Invesco Ltd. Has $269.82 Million Stock Holdings in AstraZeneca PLC $AZN

Invesco Ltd. grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,861,210 shares of the company’s stock after acquiring an additional 53,688 shares during the period. Invesco Ltd.’s holdings in AstraZeneca were worth $269,821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. SCS Capital Management LLC acquired a new position in shares of AstraZeneca during the 1st quarter valued at about $3,066,000. Robbins Farley bought a new stake in AstraZeneca during the second quarter worth approximately $1,857,000. Oliver Luxxe Assets LLC grew its holdings in AstraZeneca by 6.0% during the second quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after purchasing an additional 4,449 shares during the last quarter. Jennison Associates LLC raised its position in shares of AstraZeneca by 15.2% in the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after purchasing an additional 1,605,133 shares during the period. Finally, Alhambra Investment Management LLC acquired a new stake in shares of AstraZeneca in the second quarter worth $320,000. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AZN. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a report on Wednesday. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a report on Wednesday. Jefferies Financial Group initiated coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating on the stock. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $91.67.

AstraZeneca Trading Up 0.2%

Shares of AZN opened at $90.18 on Friday. The stock’s 50-day moving average price is $86.06 and its 200 day moving average price is $78.45. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $279.69 billion, a price-to-earnings ratio of 29.96, a P/E/G ratio of 1.67 and a beta of 0.32. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $94.01.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. The company had revenue of $15.19 billion for the quarter, compared to analyst estimates of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.AstraZeneca’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.08 EPS. As a group, research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.